DOCSLIB.ORG

Inflection Reflection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inflection Reflection Perspectives on Progress | ANNUAL REPORT 2009–2010 INFLECTION REFLECTION A celebration of achievement and discovery. INFLECTION The advancement of genomics research over the past 10 years has surpassed the expectations of even the most enthusiastic observers. While it took years and cost $3 Billion to sequence the first human genome, the same task can now be done in weeks and for less than $50,000. Gigabytes of complex raw genomic data can be digested and analyzed at previously unimaginable speeds by sophisticated bioinformatics tools. Metabolomic, proteomic and systems biology technologies are expanding scientists’ views into cellular behaviour—pointing the way to new arenas of discovery. Genomics has reached an inflection point, poised to harness the power of technology to translate the last decade of research into applications that radically improve human health, strengthen economic competitiveness and enrich our society—enhancing quality of life for all Canadians. REFLECTION Since its inception in 2000, Genome Canada has played a pivotal role in the establishment and growth of this country’s genomics research sector. In this anniversary year, the organization took the opportunity to reflect on the achievements of the past—and ready itself for the oppor­ tunities of the future. Message from the Minister of Industry . ............................... 2 Message from the Minister of State (Science and Technology) . ............. 3 Message from the Chair . 4 Human Health . ................................................. 6 Reflection: Dr. Henry Friesen . 8 Technology . 10 Reflection: Dr. Thomas Hudson . 12 Economy. .................................................... 14 Reflection: Dr. Jörg Bohlmann . 16 Society . 18 Reflection: Dr. Bartha Maria Knoppers . 20 The Look Ahead: Perspectives from Canada’s Genome Centre Leaders . 22 Performance and Objectives . 26 Notes on Governance . 36 Management Discussion . ........................................ 46 Outlook 2010–11. .............................................. 53 Contents Financial Statements . ........................................... 54 Message froM the Minister of industry Science and technology have always played an Genome Canada has proven to be a valuable instrument of the government’s important role in human progress, but are argu- Science and Technology Strategy. The research it has funded, the partnerships it ably more tightly interwoven in our daily lives has forged, both within and outside of Canada, and the infrastructure support made today than at any other point in history. They available to Canadian researchers have helped to propel our country to a leadership hold the keys to Canada’s economic prosperity, position on the world stage of genomics. our health and social well-being. I congratulate the staff, executive and directors of Genome Canada for their I am proud to acknowledge Genome Canada’s collective achievement on the occasion of the organization’s tenth anniversary, considerable contribution to this country’s and I look forward to seeing the ways in which genomics will enhance Canada’s scientific endeavours over the past 10 years. competitiveness and quality of life as its discoveries are applied in the years to come. Since Genome Canada’s inception, the first Sincerely, sequencing of the human genome has spawned thousands of new discoveries that are saving lives today, transforming industries and deepening our understanding of the fabric of life on this planet. The Honourable Tony Clement Minister of Industry 2 • GENOME CANADA | ANNUAL REPORT 2009–2010 Message froM the Minister of STATE (sCienCe and teChnology) Over the past 10 years, Genome Canada has Our government recognizes the importance of Genome Canada’s efforts—and is supported scientific research on the frontier committed to seeing research in this vital area continue. To demonstrate that com- of genomics and proteomics. mitment, Budget 2010, Leading the Way on Jobs and Growth provided Genome Canada with $75 million in new funding to support its Science and Technology In exploring the building blocks of life, Innovation Centres and a large-scale research competition. Genome Canada-funded researchers have identified the causes of debilitating and, in some I know I am not alone in looking forward to seeing how genomics discoveries will cases, lethal diseases. They have discovered ways continue to improve the lives and livelihoods of Canadians. I want to congratulate to make crops hardier; to preserve fish stocks; Genome Canada on entering its second decade as a facilitator of scientific progress to cultivate healthier forests. They have driven in Canada. the development of new technologies that extend Sincerely, Canada’s research capabilities—and have made those technologies available to other Canadian researchers, strengthening our country’s scien- tific foundation. The Honourable Gary Goodyear Minister of State (Science and Technology) GENOME CANADA | ANNUAL REPORT 2009–2010 • 3 Message froM the Chair The evidence that Canada’s genomics enterprise only by funding large-scale research projects but also by building the technological has reached an inflection point is all around us. infrastructure to enable discovery, and by forging connections with international People’s lives are being saved by genetic scientists and consortia. screening for heritable diseases that are 2010 marks Genome Canada’s 10th anniversary, affording the opportunity for the otherwise undetectable. Science-driven entre- organization to reflect on the progress made during its first decade and consider preneurs are commercializing genomic solutions. where it will be needed most in the years to come—supporting researchers’ efforts With the knowledge and technologies at their to apply their discoveries, fostering commercialization, and expanding Canada’s disposal, Canadian scientists have been the capabilities in key areas such as health, agriculture, the environment, forestry, first in the world to sequence the genomes and fisheries. of epidemic viruses such as SARS virus and last year’s ‘swine flu’, H1N1. Over the course of 2009–10, Genome Canada underwent some significant transitions. In the spring, my predecessor, Dr. Calvin Stiller, concluded his term as Board Chair Research is being translated into applications that are poised to deliver significant after six years of outstanding service. My fellow Board members and I thank him benefits for human health, economic prosperity and overall social wellbeing. for his commitment and exemplary stewardship of the organization. The opportunities associated with this ‘inflection’ are enormous. For example, as researchers discover the genetic causes of disease, pharmaceutical manufacturers In October 2009, after a tenure of impassioned and visionary leadership, founding can develop finely targeted drugs for treatment—improving outcomes and accessing President and CEO Dr. Martin Godbout stepped down. Martin was among those a multi-billion dollar market. ‘pioneers’ who early on recognized the significance genomics would have on the economy, environment and society as a whole. We are all grateful for his inspiring Genome Canada is committed to seeing that the opportunities of genomics are work, and for establishing the strong foundation that Genome Canada will build on realized for Canadians and the world. The organization has played an essential in the years to come. role in the development of the country’s genomics capabilities since 2000, not 4 • GENOME CANADA | ANNUAL REPORT 2009–2010 Through its activities and programs—in partnership with federal departments and The Board was pleased to appoint Mr. Dale Patterson to the position of interim agencies—Genome Canada will continue to play a role in strengthening Canada’s CEO by year’s end—and pleased also to have the federal government acknowledge knowledge, people and entrepreneurial advantages, three key elements of the Genome Canada’s good work and value as an enabler of its Science and Technology Government of Canada’s Science and Technology Strategy. It will continue to play a Strategy by allocating $75 Million to Genome Canada in its 2010 Budget. leadership role in addressing the ethical, environmental, economic, legal and social I look forward to leading the Board through the coming year as we begin to see the (GE3LS) implications of genomics research. outcomes of this inflection point genomics has reached—and as the benefits of the Genome Canada will also continue to raise Canadians’ awareness of their country’s country’s scientific leadership begin to multiply. genomics success, and of the potential genomics has to improve their lives. Last year, Sincerely, Genome Canada commissioned an EKOS Research Associates survey of public attitudes toward genomics. We were gratified to learn that 82 percent of Canadians are supportive of genomics research and 45 percent have some familiarity with it (up from just a third in 2001). I must thank everyone within the organization, and particularly the members of the C. Thomas Caskey, M.D., FACP joint Board-management transition team established last fall, for their commitment Chair and perseverance over the course of what was a very busy time. The organization not only maintained its operations successfully as it began the search for a new President and CEO, but in fact advanced its strategic thinking and direction. GENOME CANADA | ANNUAL REPORT 2009–2010 • 5 HUMAN HEALTH PuTTING LIFESAvING TOOLS IN THE HANDS OF healthcare PRACTITIONERS Genomics and proteomics are changing the
Load more

Recommended publications
  • News Release
    NEWS RELEASE: June 14, 2005 Health care leaders create Canada’s first national health advisory body The Canadian Academy of Health Sciences will give Government and the public comprehensive expertise and advice on health issues EDMONTON - When the President of the United States wants advice on a public health issue, he calls the United States’ National Academies. When the Prime Minister of Great Britain wants to seek similar counsel, he usually turns to the Royal Society of Britain. But when the Prime Minister of Canada wants similar advice, who does he call? Well, that’s not always entirely clear, given the more narrowly defined mandates of many Canadian organizations. Now, however, owing to a recent initiative by a group of leading health care leaders and researchers, the Prime Minister will be able to call the Canadian Academy of Health Sciences (CAHS), recently created to: • Develop informed, strategic assessments on urgent health issues; • Inform public policy on these issues; • Enhance Canada’s readiness to deal with global health issues; and, • Provide a recognized and authoritative Canadian health science voice internationally. According to one of the Academy’s key organizers, the establishment of the Academy is long over due—and all the more pressing given the potential global health threats to Canadians, most recently exemplified by the SARS threat. “Ask Canadians what they care about most, and they answer unequivocally: ‘health,’” explains University of Alberta Professor of Medicine Paul Armstrong, CAHS’s first president. “It makes sense, therefore, that Canada should have an organization that government—and Canadians—can turn to for sound, impartial advice and research on pressing health issues.” The organization will also have an international role to play, representing Canada’s interests abroad and working closely with other nations’ parallel agencies.
    [Show full text]
  • The Committee
    2016-2017 Annual Report Faculty of Medicine Honours and Awards Committee Table of Contents 2 3 Committee 4 Background and Analysis 5 Faculty Laureates Committee 3 The Faculty of Medicine’s Honours and Awards Committee was struck in July 2010 to advise the Dean and Faculty on matters related to Honours and Awards. It meets several times each year to discuss ongoing and upcoming awards opportunities and overall policies and is comprised of faculty members chosen for their expertise in mentorship and leadership. The Committee is meant to enhance the existing nomination process for faculty rather than replace it, and operates in conjunction with departmental committees and the University Prizes and Awards Committee (UPAC). In general, the Honours and Awards Committee does not veto nominations and faculty members are free to nominate at their own discretion. An exception occurs when there are restrictions included in the prize guidelines regarding the number of nominations allowed per institution or faculty. While it is not necessary to involve the Committee with every nomination, it is useful to make the Committee aware of nominations or even the intention to nominate within the Faculty, particularly with regards to high-profile awards, as our office can often provide guidance and support. A list of awards the Committee regularly works with can be found here. Exclusions It should be noted that, with some exceptions, the recognition opportunities considered by the Honours and Awards Committee exclude: Investigator awards or career awards tied to grant submissions Fellowships that provide emancipation from university responsibilities Education or leadership awards Self-nominations Awards for students or postdoctoral fellows The selection of endowed chairs Administrative/support staff-specific awards Committee Members, 2016–2017 Abraham Fuks, Chair Philip E.
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • CURRICULUM VITAE February 2019 NAME TSUI, Lap-Chee POSTAL
    CURRICULUM VITAE February 2019 NAME TSUI, Lap-Chee POSTAL ADDRESS Victor and William Fung Foundation 33/F Alexandra House 18 Chater Road Central Hong Kong SAR China E-MAIL ADDRESS [email protected] PERSONAL DATA Date of Birth: 21 December 1950 Place of Birth: Shanghai, China Sex: Male Marital Status: Married (2 children) Citizenship: Canadian EDUCATION BSc (Biology, 1972) The Chinese University of Hong Kong MPhil (Biology, 1974) The Chinese University of Hong Kong PhD (Biological Sciences, 1979) University of Pittsburgh POSTGRADUATE TRAINING 1972-1974 Graduate Student, Department of Biology, New Asia College, The Chinese University of Hong Kong (Supervisor: Dr KK Mark) 1974-1979 Graduate Student, Department of Biological Sciences, University of Pittsburgh (Supervisor: Dr Roger W Hendrix) 1979-1980 Postdoctoral Investigator, Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee (Supervisor: Dr Wen K Yang) 1981-1983 Postdoctoral Fellow, Department of Genetics, The Hospital for Sick Children, Toronto, Ontario (Supervisor: Dr Manuel Buchwald) CURRENT POSITIONS President, Victor and William Fung Foundation, Hong Kong (from August 2014) Director, Qiushi Academy of Advanced Studies, Zhejiang University, Hangzhou (from August 2014) Master, Residential College, Haining International Campus, Zhejiang University (from September 2016) President, The Academy of Sciences of Hong Kong (from November 2015) Emeritus University Professor, University of Toronto (from 2006) Adjunct Scientist, Research Institute, The Hospital for Sick Children,
    [Show full text]
  • Annual Summary Corporate Plan 2010
    THE GAIRDNER FOUNDATION Annual Summary Corporate Plan 2010 1 TABLE OF CONTENTS PAGE Section I About the Gairdner Foundation 4 Objectives and Achievements to Date 8 Economic Benefits 9 Section II Performance Results for 2009 Activities 10 Detailed 2009 Evaluations 11-14 Planned Activities and Anticipated Results 2010 15 Section III Financial Summary 16 Planned Receipts and Disbursements 2010 18 Section IV Risk Management 19 Section V Performance Monitoring 21 2 "Receiving the Gairdner Award is not only a tremendous honor. It is also an induction into the Gairdner family of exceptional biomedical scientists. The 50th anniversary celebration was a joyous family reunion." Gairdner (1981) and Nobel Laureate, Michael Brown, Southwestern University, Dallas 3 THE GAIRDNER FOUNDATION CORPORATE PLAN EXECUTIVE SUMMARY HISTORY The Gairdner Foundation was created in 1957 by James Arthur Gairdner to recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life. Since the first awards were made in 1959, the Gairdner Awards have become Canada's foremost international award. The Canada Gairdner International Awards are one of the three most prestigious awards in medical science, along with the Swedish Nobel Prize in Medicine and the American Albert Lasker Medical Research Awards. They hold up the pinnacle of achievement as a mirror to Canadians, and in so doing, play a role in helping Canada achieve its goals of excellence. The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. Its funds originally derived from the personal gifts of the founder and members of his family.
    [Show full text]
  • 2018 Spotlight Newsletter of FCIHR
    2018 Spotlight on FCIHR No. IX December 2018 2018 Friesen Prize Lecture at U Ottawa – November 6th, 2018 – Left to Right: Dr. Lorne Tyrrell (Director, Li Ka Shing Institute of Virology, U Alberta), Dr. Bernard Jasmin (Dean of Med, U Ottawa), Dr. Henry Friesen (Distinguished Prof. Emeritus, U Manitoba), Dr. Alex MacKenzie (Senior Scientist, CHEO RI; FCIHR Exec.), Dr. Mona Nemer (Chief Scientist of Canada), Dr. David Naylor (President Emeritus, U of T; 2018 Friesen Prizewinner), Dr. Aubie Angel (President, FCIHR), Dr. Janet Rossant (President, Gairdner Foundation; 2016 Friesen Prizewinner), Dr. Alan Bernstein (President, CIFAR; 2017 Friesen Prizewinner), Dr. Bruce McManus (CEO, PROOF Centre, UBC; FCIHR Exec.) & Dr. Linda Rabeneck (President, CAHS; FCIHR Board). MESSAGE FROM THE PRESIDENT 2018 was replete with significant milestones in health research in Canada, starting with a substantial increase in the funding of Science. This was driven in part by the Federal government’s vision of a knowledge-based economy and of the wide endorsement of Dr. David Naylor’s Report on “Canada’s Fundamental Science Review”. As well, insightful and effective leadership of CIHR with Dr. Rod McInnes, as Acting President, stabilized a fractured institution and set the stage for the 2018 Friesen Prize Award Presentation to appointment of our new President, Dr. Michael Dr. David Naylor Strong (past Dean of Med, UWO), as of October 1st, 2018. Congratulations and thank you to Dr. Strong L to R: Dr. Henry Friesen (Distinguished Prof. Emeritus, U for taking on this vital responsibility, on behalf of Manitoba), Dr. Alan Bernstein (President, CIFAR; 2017 Canada’s health science community.
    [Show full text]
  • Canada's Contribution to Respiratory Physiology and Pathophysiology
    10427_macklem.qxd 02/10/2007 11:04 AM Page 383 SPECIAL ARTICLE Canada’s contribution to respiratory physiology and pathophysiology Peter T Macklem MD t is an almost impossible task to describe Canadian contribu- that clinical research was part of his training program, and as a Itions to respiratory physiology and pathophysiology. There result, Christie published a series of classical papers in respira- have been so many and they have been so important that it is tory medicine. As shown in Figure 1, he was one of the first to difficult to pick and choose. Inevitably, there will be omissions; make sense out of the subdivisions of lung volume (1). He inevitably, some of us will not be pleased; and inevitably, one is measured pleural pressure in normal subjects (Figure 2), as well biased by one’s own experience. This will affect what I write, as in patients with congestive heart failure (Figure 3) and no matter how much I strive for objectivity. I apologize to any- emphysema, and showed that emphysema was characterized by one whose contributions I should have described but failed to loss of lung elastic recoil (2-4). Research in respiratory physi- do so. And to those whose work I do describe, I hope I have got ology and pathophysiology began in Canada. it right. Joe Doupe was a physiologist at the University of Manitoba, The focus of the present review is on the roots of respiratory Winnipeg, Manitoba. He was an original thinker and passed on physiological and pathophysiological research in Canada, and his ideas to medical students and residents.
    [Show full text]
  • Dr. Henry G. Friesen
    The Henry G. Friesen International Prize in Health Research was established in recognition of Dr. Friesen’s distinguished leadership, vision and innovative contributions to health research and health research policy. The award, announced each spring, supports an annual fall lecture or series of lectures by a worthy and accomplished speaker of international stature on topics related to the advancement of health research and its evolving contributions to society. The lecture endeavours to reach the broadest possible audience at major centres across Canada. The Prize provides a significant cash award and covers the travel and hospitality costs of the Honouree. The Prize is a joint project of Friends of CIHR with the Canadian Academy of Health Sciences and financed through a fund established for that purpose. Broadcast partner is CBC Radio One. HENRY G. FRIESEN A renowned and visionary medical scientist, Dr. Henry Friesen is a Canadian endocrinologist credited with the discovery of human prolactin, and for redefining medical research in Canada. Now a Distinguished Professor Emeritus of the University of Manitoba, Dr. Friesen was a Professor and Head of the Department of Physiology and Professor of Medicine. As President of the former Medical Research Council of Canada, he brought together scholars, scientists, practitioners, governments, industry, and patient groups, and inspired the creation of the Canadian Institutes of Health Research. His integrity and selfless idealism attracted the support of thousands of advocates and admirers, both nationally and internationally. He fostered and nurtured the creation of Friends of CIHR. Dr. Friesen was President of the National Cancer Institute of Canada and President of the Canadian Society for Clinical Investigation.
    [Show full text]
  • Nouvelles Nouvelles
    NNOUVELLESOUVELLES Seven new inductees named to Canadian Medical Hall of Fame Membership in the Canadian Medical This year’s inductees include another • Dr. Frederick Montizambert Hall of Fame now stands at 49, after 7 politician, former Alberta Premier Peter (1843–1929), Canada’s first director gen- new inductees were named Mar. 22. The Lougheed, founder of the Alberta Her- eral of public health and promoter of the hall, based in London, Ont., named its itage Fund for medical research. The need for a federal Department of Health; first 10 members in 1994. It was created other 2001 inductees are: • Dr. Lucille Teasdale-Corti to honour Canadians who have “con- • Dr. Henry Friesen, former presi- (1929–96), Canadian surgeon who dedi- tributed to the understanding of disease dent of the Medical Research Council of cated her professional life to the people and the advancement of health and the Canada and a “role model of scientists”; of Uganda, where she founded a school well-being of people everywhere.” • Dr. John Bradley, promoter and or- of nursing and helped found a hospital It is now a Who’s Who of Canadian ganizer of the Alberta Heritage Fund for before her life was claimed by AIDS. medicine and medical research, with medical research; This year’s induction ceremony will members ranging from Frederick Banting, • Dr. Charles Scriver, founder of the take place Oct. 12, 2001, as part of a Charles Best and William Osler to more De Belle Laboratory in Biochemical Ge- province-wide youth symposium at the recent inductees such as astronaut Roberta netics at the Montreal Children’s Hos- University of Manitoba.
    [Show full text]
  • Lauréats 2007 Table Des Matières
    2007 LAURÉATS TABLE DES MATIÈRES Mot des ministres PAGE 5 Historique des Prix du Québec PAGE 7 Membres des jurys PAGE 52 Médaille des Prix du Québec PAGE 55 Paul Chamberland Yves Bergeron Richard E. Tremblay PRIX ATHANASE-DAVID PRIX MARIE-VICTORIN PRIX LÉON-GÉRIN PAGE 8 PAGE 12 PAGE 16 Jacques Lacoursière Yves Morin Jacques Y. Montplaisir PRIX GÉRARD-MORISSET PRIX ARMAND-FRAPPIER PRIX WILDER-PENFIELD PAGE 32 PAGE 36 PAGE 40 Rober Racine Paul Hébert Pierre Mignot PRIX PAUL-ÉMILE-BORDUAS PRIX DENISE-PELLETIER PRIX ALBERT-TESSIER PAGE 20 PAGE 24 PAGE 28 Gaston Bellemare Maher I. Boulos PRIX GEORGES-ÉMILE-LAPALME PRIX LIONEL-BOULET PAGE 44 PAGE 48 Voyez les entrevues avec les lauréats dans le site Web des Prix du Québec à l’adresse suivante : www.prixduquebec.gouv.qc.ca 04 MOT DES MINISTRES PRIX DU QUÉBEC LAURÉATS 2007 05 Une société progresse lorsque ses membres permettent à leur passion, leur flamme intérieure, leur créativité et leur dévouement de s'exprimer avec conviction. Parmi ces êtres se trouvent des gens qui forcent l’admiration par leur puissant désir de se dépasser pour le bien commun. Leur maîtrise de connaissances de pointe contribue à façonner une culture d'excellence, une culture moderne et Uouverte sur le monde. Depuis 1977, le gouvernement québécois a l’agréable tâche de rendre hommage, par l’entremise des Prix du Québec, à ces personnes remarquables qui, par leur savoir, leur ténacité et leur vision, contribuent au rayonnement de nos atouts autant chez nous qu’au-delà de nos frontières. Au nom des Québécoises et des Québécois, nous tenons à exprimer toutes nos félicitations et notre sincère reconnaissance à MM.
    [Show full text]
  • 82800G Iacsnews 10/12/06 11:34 Page 29 82800G Iacsnews 10/12/06 11:34 Page 30
    82800g IACSnews 10/12/06 11:34 Page 29 82800g IACSnews 10/12/06 11:34 Page 30 3 0 82800g IACSnews 10/12/06 11:34 Page 31 Global Conference on Heart Health & Disease Program All events at Winnipeg Convention Centre unless otherwise noted. All symposia on 2nd Floor except where indicated on 1st Floor. Speakers’ Prep Room - Cecil Richards Suite - 2nd Floor. Co-Chairs: Lee and Albert Friesen Oct. 12, Thursday 7:00 - 9:30 PM Reception to Celebrate the 10th Anniversary of IACS at the Manitoba Legislative Building (under the Golden Boy) (Buses will depart from the Winnipeg Convention Centre York Ave. entrance at 6:45 PM) supported by Manitoba Liquor Marts Oct. 13, Friday 7:15 -7:50 AM Breakfast (Presentation Theatre Concourse - 2nd Floor) University of Manitoba Faculty of Medicine Symposium “Developments in Cardiovascular Science and Medicine” Keynote Lectures (Presentation Theatre - 2nd Floor) Chairs: Senator Wilbert Keon, Ottawa, Canada Academician Eugeny Chazov, Moscow, Russia Speakers: 7:55 - 8:25 AM Peter Liu, Director, CIHR Institute of Circulatory and Respiratory Health, Toronto, Canada: Strategic Vision for Cardiovascular Research in Canada 8:25 - 8:55 AM His Excellency Ismail Sallam, Former Health Minister of Egypt, Cairo, Egypt: Health for Peace and Security, New Dimensions and Potentials Symposia Sessions Symposium #1 Room 2E Chairs: Robert B. Jennings, Durham, USA K. Gopal Nair, Mumbai, India Speakers: 9:00 - 9:20 AM Paul Armstrong, Edmonton, Canada: Acute myocardial infarction is an inflammatory matter. 9:20 - 9:40 AM William Weglicki, Washington, USA: Neurogenic inflammation of the heart. 9:40 - 10:00 AM Ursula Muller-Werdan, Halle, Germany: Inflammation and the aging heart.
    [Show full text]
  • The Role of Expectations of Science As Promissory Discourses in Shaping Research Policy: a Case Study of the Creation of Genome Canada
    The Role of Expectations of Science as Promissory Discourses in Shaping Research Policy: A Case Study of the Creation of Genome Canada by Margaret Amanda Lemay A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Leadership, Higher and Adult Education University of Toronto © Copyright by Margaret Amanda Lemay 2019 The Role of Expectations of Science as Promissory Discourses in Shaping Research Policy: A Case Study of the Creation of Genome Canada Margaret Amanda Lemay Doctor of Philosophy Department of Leadership, Higher and Adult Education University of Toronto 2019 Abstract This thesis examines promise of science discourse and its impacts in shaping research policy. Through a single case study of the origins of Genome Canada, the research was guided by the question: How did expectations of genomics, as promise of genomics discourse, shape the creation of Genome Canada? Background is presented on the long-standing, but largely unacknowledged, relationship between the promise of science and research policy. Theoretical grounding for the study is provided by concepts from the discursive policy analysis and sociology of expectations of science and technology literatures. Promise of genomics discourse, expectations of genomics of story-lines and a conceptualization of knowledge-based discursive power provide the theoretical and analytical basis for an in-depth examination of the ideational effects and material impacts on research policy decisions over three years (1997 – 2000) that sought to position Canada as a leader, internationally, in genomics research. As discourse, the promise of genomics fulfilled an essential role in shaping policy decisions. The promise of genomics discourse and expectations of genomics story-lines functioned in a complex interplay of discursive practices and dynamics among diverse policy actors within a promise of genomics discourse-coalition to produce a range of ideational and material impacts.
    [Show full text]